% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Korshunov:128073,
author = {A. Korshunov$^*$ and D. Schrimpf$^*$ and M. Ryzhova and D.
Sturm$^*$ and L. Chavez$^*$ and V. Hovestadt$^*$ and T.
Sharma$^*$ and A. Habel$^*$ and A. Burford and C. Jones and
O. Zheludkova and E. Kumirova and C. M. Kramm and A. Golanov
and D. Capper$^*$ and A. von Deimling$^*$ and S. Pfister$^*$
and D. Jones$^*$},
title = {{H}3-/{IDH}-wild type pediatric glioblastoma is comprised
of molecularly and prognostically distinct subtypes with
associated oncogenic drivers.},
journal = {Acta neuropathologica},
volume = {134},
number = {3},
issn = {1432-0533},
address = {Berlin},
publisher = {Springer},
reportid = {DKFZ-2017-04095},
pages = {507 - 516},
year = {2017},
abstract = {Pediatric glioblastoma (pedGBM) is an extremely aggressive
pediatric brain tumor, accounting $for ~6\%$ of all central
nervous system neoplasms in children. Approximately half of
pedGBM harbor recurrent somatic mutations in histone 3
variants or, infrequently, IDH1/2. The remaining subset of
pedGBM is highly heterogeneous, and displays a variety of
genomic and epigenetic features. In the current study, we
aimed to further stratify an H3-/IDH-wild type (wt) pedGBM
cohort assessed through genome-wide molecular profiling. As
a result, we identified three molecular subtypes of these
tumors, differing in their genomic and epigenetic signatures
as well as in their clinical behavior. We designated these
subtypes $pedGBM_MYCN$ (enriched for MYCN amplification),
$pedGBM_RTK1$ (enriched for PDGFRA amplification) and
$pedGBM_RTK2$ (enriched for EGFR amplification). These
molecular subtypes were associated with significantly
different outcomes, i.e. $pedGBM_RTK2$ tumors show a
significantly longer survival time (median OS 44 months),
$pedGBM_MYCN$ display extremely poor outcomes (median OS
14 months), and $pedGBM_RTK1$ tumors harbor an intermediate
prognosis. In addition, the various molecular subtypes of
H3-/IDH-wt pedGBM were clearly distinguishable from their
adult counterparts, underlining their biological
distinctiveness. In conclusion, our study demonstrates
significant molecular heterogeneity of H3-/IDH-wt pedGBM in
terms of DNA methylation and cytogenetic alterations. The
recognition of three molecular subtypes of H3-/IDH-wt pedGBM
further revealed close correlations with biological
parameters and clinical outcomes and may therefore, be
predictive of response to standard treatment protocols, but
could also be useful for stratification for novel,
molecularly based therapies.},
cin = {G380 / L101 / B062 / B060},
ddc = {610},
cid = {I:(DE-He78)G380-20160331 / I:(DE-He78)L101-20160331 /
I:(DE-He78)B062-20160331 / I:(DE-He78)B060-20160331},
pnm = {312 - Functional and structural genomics (POF3-312)},
pid = {G:(DE-HGF)POF3-312},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:28401334},
doi = {10.1007/s00401-017-1710-1},
url = {https://inrepo02.dkfz.de/record/128073},
}